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Abstract 
Objective:  The  purpose  of  this  study  was  to  evaluate  the  relationship  between  5,10- 
methylenetetrahydrofolate reductase (MTHFR) polymorphisms and Attention Deficit Hy-
peractivity Disorder (ADHD) in a sample of Turkish children. 
Study Design: MTHFR gene polymorphisms were assessed in 40 patients with ADHD and 
30 healty controls. Two mutations in the MTHFR gene were investigated using polymerase 
chain reactions and restriction fragment length polymorphisms. 
Results: Although there were no statistically significant differences in genotype distributions 
of the C677T alleles between the ADHD and the control groups (p=0,678) but the genotypic 
pattern of the distributions of the A1298C alleles was different between the ADHD patients 
and the controls (p=0,033).  
Conclusions:  Preliminary  data  imply  a  possible  relationship  between  A1298C  MTHFR 
polymorphisms and the ADHD. 
Key  words:  Attention  deficit-hyperactivity  disorder,  methylenetetrahydrofolate  reductase  gene 
polymorphism, folic acide 
Introduction 
Attention  Deficit  Hyperactivity  Disorder 
(ADHD)  is  a  common  childhood  neurobehavioural 
disorder  defined  by  symptoms  of  developmentally 
inappropriate  inattention,  impulsivity  and  hyperac-
tivity.  A  recent  meta-analysis  estimated  the  world-
wide prevalence of ADHD to be 5.29% [1], making it 
the most prevalent psychiatric disorder of childhood. 
The social and economic  costs  of childhood ADHD 
are considerable [2], and difficulties often persist into 
adulthood. Children with ADHD are at high risk for 
developing  adjustment  problems,  antisocial  behav-
iour, substance abuse, other psychiatric disorders, and 
difficulties in education and work [3]. Although the 
exact aetiology of ADHD  has not been determined, 
the  related  factors  include  familial  and  hereditary 
factors, prenatal or perinatal factors, chemotoxic fac-
tors,  sociopsychological  stress,  structural  and  func-
tional abnormalities of the brain, and developmental 
neurobiological factors in the regions of the brain re-
lated to ADHD [4]. Family, twin, and adoption stud-
ies provide overwhelming evidence for an inherited 
contribution to the pathogenesis of ADHD, with her-
itability estimated to be about 70% [5].  
Methylenetetrahydrofolate  reductase  (MTHFR) 
is important for a chemical reaction involving forms 
of the vitamin folate (also called folic acid or vitamin 
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B9).  Specifically,  this  enzyme  converts  5,10- 
methylenetetrahydrofolate  to  5-methyltetrahydro-
folate, the predominant circulating form of folate. This 
reaction  is  required  for  the  multistep  process  that 
converts  the  amino  acid  homocysteine  to  another 
amino acid, methionine. The body uses methionine to 
make proteins and other important compounds. The 
5,10 methylenetetrahydrofolate reductase gene is lo-
cated  at  the  end  of  the  short  arm  of  chromosome 
1p36.3 [6]. The enzyme plays a central role in folate 
metabolism  by  irreversibly  converting  5,10-methy-
lenetetrahydrofolate to 5-methylenetetrahydrofolate.  
5-Methyltetrahydrofolate  is  the  predominant 
circulating  form  of  folate,  and  it  donates  a  methyl 
group  to  homocysteine  in  the  generation  of 
S-adenosylmethionine,  a  major  source  of  methyl 
groups in the brain [7]. MTHFR is a critical component 
of  the  1-carbon  cycle,  and  the  polymorphisms  of 
C677T  and  A1298C affect both  nucleotide  synthesis 
and DNA methylation [8]. Heterozygous and homo-
zygous  carriers  of  the  677T  allele  variant  have  a 
30–40% and 60–70% reduced enzyme activity, respec-
tively,  as  determined  by  in  vitro  analysis  of  the 
MTHFR activity [9,10]. The effect of the 1298C allele 
variant is less severe and homozygous carriers of this 
allele have a more moderate 30–40% reduction of the 
enzyme activity, yet its function remains controversial 
[11]. The MTHFR C677T polymorphism is associated 
with a reduction  in  the bioavailability of folate  and 
folate  metabolites  and  "mimics"  low  dietary  folate 
intake [12]. 
Recent  studies  showed  that  genetic  polymor-
phism of MTHFR is related to neuropsychiatric dis-
eases such as schizophrenia, depression, bipolar dis-
order, Parkinson’s disease, Alzheimer’s disease, and 
vascular dementia [13-16]. These studies have gener-
ally been carried out in adults and there are insuffi-
cient  numbers  of  studies  about  the  relationship  of 
childhood neuropsychiatric problems with folic acid 
and MTHFR that plays a central role in folate metab-
olism. In addition, these few studies in pediatric pop-
ulation are related to Autism [17] and ADHD. Studies 
on the relationship of ADHD with folic acid and folic 
acid  metabolism  have  focused  on  the  childhood 
symptoms of folic acid deficiency in antenatal period 
[18,19].  Although  many  studies  have  examined 
ADHD related genes, only one study has focused on 
the role of MTHFR. This single study evaluated chil-
dren  with  ADHD  symptoms  after  leukemia  treat-
ment, rather than children with a diagnosis of ADHD 
[20]. In our study, we aimed to determine the rela-
tionship  between  common  MTHFR  gene  mutations 
(C677T and A1298C) and ADHD, a disorder that ge-
netic factors play an important role in its etiology.  
Materials and Methods 
Participants  
Forty patients with ADHD and 30 healthy vol-
unteers were included in the study. The ADHD group 
consisted of consecutive referrals to the child and ad-
olescent  psychiatry  outpatient  clinic  of  Konya  Re-
search  Hospital  between  October  2009  and  March 
2010.  A  total  of  72  subjects  were  approached  to  be 
included in the study group. Of those 20 subjects were 
excluded because of non-consent and 12 subjects were 
excluded because of exclusion criteria.  
Exclusion criteria were as follows: (a) having an 
IQ below than 80 on Weschler Intelligence Scale for 
Children-Revised  (WISC-R),  (b)  diagnosis  of  perva-
sive developmental disorders, (c) presence of psycho-
sis,  drug  dependence,  and  medical  or  neurological 
diseases, (d) evidence of a history of physical and/or 
sexual abuse. Finally a total of 40 subjects were in-
cluded in the study. The control group consisted of 
children  of  hospital  employees  or  members  of  the 
general community who became aware of the study 
via the principal investigators or other participants. 
Assessments  
The diagnosis of ADHD was made on the basis 
of DSM-IV criteria. There were 31 male and 9 female 
patients  with  ADHD  with  an  age  range  of  6  to  17 
years (mean ± SD: 9.77±2.3), and 23 male and 7 female 
controls  with  an  age  range  of  6  to  17  (mean  ±  SD: 
10.5±4.5). All ADHD patients had the symptoms of 
inattention and hyperactivity/impulsivity, which was 
recognized by DSM-IV as ADHD-combined type and 
none of the children have ADHD to the control group.  
The  clinical  assessment  included  the  following 
parts:  (1)  The  Schedule  for  Affective  Disorders  and 
Schizophrenia  for  school-age  children,  lifetime  ver-
sion [21], which is a semi-structured diagnostic inter-
view designed to assess current and past episodes of 
psychopathology in children and adolescent accord-
ing to DSM-IV (and DSM-III-R) criteria. KSADS was 
administered  to  clinically  diagnosed  patients  with 
ADHD  and  their  parents  to  confirm  diagnosis  of 
ADHD,  (2)  The  ADHD  Rating  Scale-IV  [22]  which 
contains 18 items referring to the diagnostic criteria of 
the DSM-IV; 9 items indicating inattention symptoms, 
and  9  items  indicating  hyperactivity-impulsivity 
symptoms. Each item is rated for frequency of symp-
tom on a 4-point Likert scale, ranging from 0 (rarely) 
to 3 (very often). Scores of 2 or 3 on individual items 
were regarded as indicating the presence of a symp-
tom. Total scores varied between 0–54. (3) The IQ was 
assessed by using the Manual for the Weschler Intel-
ligence Scale for Children-Revised [23].  Int. J. Med. Sci. 2011, 8 
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Family  and  medical/perinatal/developmental 
histories of the patients were obtained from the par-
ents.  A  local  ethical  committee  in  Konya  Research 
Hospital,  Konya,  Turkey  approved  the  study.  A 
written  informed  consent  was  obtained  from  the 
parents.  
Determination of The Folic Acid Levels 
Totally 4-5 ml of blood samples were drawn after 
a 12-14 hours of fasting in the morning. Sera of the 
samples were separated after coagulation and stored 
at -85oC until the day of analysis. Serum folate levels 
were determined in Elecsys 2010 auto analyzer (Roche 
Diagnostics,Indianapolis,  IN,  USA)  by  using  cobas 
test kit (lot no: 160-446-02). 
Determination of MTHFR Gene Mutations 
Genomic DNA of patients and controls was iso-
lated  from  peripheral  blood  samples  using  the  QI-
Aamp DNA Blood Mini  Kit (Qiagen, Valencia, CA, 
USA). The extracted genomic DNA samples then un-
derwent  polymerase  chain  reaction  (PCR)  to  screen 
for  and  amplify  two  MTHFR  gene  mutations;  one 
involving base pair 677 and the other involving base 
pair 1298. The PCR reaction mix contained 5 μl ge-
nomic  DNA,  5  μl  10×  PCR  buffer  (P-2192;  Sig-
ma-Aldrich, St Louis, MO, USA), 5 μl of deoxynucle-
otide triphosphate mixture (Promega, Madison, WI, 
USA) containing 0.2 mM  of each nucleotide, 5 μl 1 
mM Tris–HCl, 5 μl 5 mM 
KCl, 0.2 μl of Taq polymerase enzyme (D- 6677; 
Sigma-Aldrich) and 4 pmol each of forward and re-
verse primers for each region. The volume was made 
up to 50 μl with double distilled water. The primers 
for each region were: base pair 677 forward 5′-AGG 
ACG  GTG  CGG  TGA  GAG  TG-3′,  reverse  5′-  TGA 
AGG AGA AGG TGT CTG CGG GA-3′; base pair 1298 
forward 5′-CTT TGG GGA GCT GAA GGA CTA CTA 
C-3′, reverse 5′-CAC TTT GTG ACC ATT CCG GTT 
TG-3′. The PCR thermal cycling conditions for each 
region were: base pair 677, an initial denaturation step 
at 95 °C for 3 min, followed by 35 cycles of 94 °C for 1 
min, 61 °C for 1 min, 72 °C for 1 min, and one last 
extension at 72 °C for 7 min; base pair 1298, an initial 
denaturation step at 92 °C for 2 min, followed by 35 
cycles of 92 °C for 2 min, 60 °C for 1 min, 72 °C for 30 
s, and one last extension at 72 °C for 7 min. The PCR 
products  for  the  base  pair  677  and  1298  mutations 
underwent restriction enzyme digestion: for base pair 
677, 15 μl of the 198 base pair PCR product was added 
into a reaction mixture containing 7 μl of double dis-
tilled water, 5 U of Hinfl enzyme (Fermentas UAB, 
Vilnius,  Lithuania)  and  2.5  μl  of  Red  (R+)  Buffer 
(Fermentas UAB); for base pair 1298, 20 μl of the 163 
base  pair  PCR  product  was  added  into  a  reaction 
mixture containing 1 U of Mboll enzyme (Fermentas 
UAB) and 0.5 μl of Blue (B+) buffer (Fermentas UAB). 
Both reactions were incubated at 37 °C for 16 h. To 
visualize the fragments formed after cleavage, 25 μl of 
digested  PCR  products  for  each  base  pair  (677 and 
1298) were loaded onto 2% or 3% ultra-pure agarose 
gel, respectively, and electrophoresed for 90 min to 
identify the alleles for each base pair mutation. For the 
base pair 677 mutation, the samples containing only 
the 198 base pair fragments were identified as 677 CC, 
the  samples  containing  198,  175,  and  23  base  pair 
fragments were identified as 677 CT, and the samples 
containing 175 and 23 base pair fragments were iden-
tified as 677 TT. For the base pair 1298 mutation, the 
samples  containing  56,  31,  20,  28  and  18  base  pair 
fragments  were  identified  as  1298  AA,  the  samples 
containing 84, 56, 31, 30, 28 and 18 base pair fragments 
were identified as 1298 AC, and the samples contain-
ing 84, 31, 30 and 18 base pair fragments were identi-
fied as 1298 CC. 
Statistical analysis 
The data of this study were analysed with SPSS 
17 package program. The statistical significance was 
defined  as  p  value  of  0.05  or  smaller.  Independent 
sample t-tests and chi-square test (Pearson Chi-Square 
and Fisher’s exact test) which is one of nonparametric 
tests were used. 
 
Results  
The age and gender distribution of the patients 
with ADHD and controls were nearly similar (Table 
1). The blood folic acid levels of patients and controls 
were found to be normal and there was no statistical 
difference (13,01 ± 2,35 versus 11,82 ± 2,72; p= 0.055). 
However, there were significant differences between 
the groups considering the scores  of ADHD Rating 
Scale-IV total (43.2 ± 2,8 versus 17.8 ± 3.9; t = 29.93; 
p=0.000);  ADHD  Rating  Scale-IV-  inattentiveness 
(21.3 ± 2,1 versus 8.5 ± 2.6; t = 22.14; p=0.000); ADHD 
Rating Scale-IV-hyperactivity/impulsivity (21.9 ± 1,6 
versus 9.2 ± 1.7; t = 31.01; p=0.000). 
There were no statistically significant differences 
in genotype distributions of the C677T alleles between 
the ADHD and control groups (p=0,678). The geno-
typic pattern of the distributions of the A1298C alleles 
was  different  between  the  ADHD  patients  and  the 
controls  (p=0,033).  We  also  compared  these  groups 
according to the compound heterozygosity. As a re-
sult, we could not detect a statistically significant dif-
ference (p=0,801). (Table 2) 
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Table 1. Description of ADHD and Control Groups 
 
 
ADHD 
 
Control 
 
p 
 
 
Age 
 
9.77 ± 2.3 
 
10.5 ± 4.5 
 
0.429 
Sex      0.935 
   Male  31 (%77.5)  23 (%76.7)   
   Female  9 (%22.5)  7 (%23.3)   
ADHD Rating Scale-IV Scores       
 Inattentiveness  21.3 ± 2.1  8.5 ± 2.6  0.000  
 Hyperactivity/impulsivity  21.9 ± 1.6  9.2 ± 1.7  0.000 
 Total  43.2 ± 2.8  17.8 ± 3.9  0.000 
Total IQ Score  100.1 ± 7.1  98.3 ± 5.6  0.273 
 
Table 2. MTHFR Gene Alleles of ADHD and Control 
Groups. 
  ADHD  Control  P 
value  n  %  n  % 
MTHFR C677T   CC  22  55  15  50  0,678 
CT and TT  18  45  15  50 
MTHFR A1298C  AA  9  22,5  14  46,7  0,033 
AC and CC  31  77,5  16  53,3 
 COMBİNED  The compound 
heterozygous* 
CT/AC 
9  22,5  6  20  0,801 
Other combina-
tions 
31  77,5  24  80 
* mutations on different alleles 
 
 
When MTHFR gene alleles were evaluated with 
respect  to  sex,  there  was  no  statistically  significant 
difference between ADHD and male control groups 
according  to  MTHFR  C677T  (p=0,61)  and  A1298C 
(p=0,173) alleles. In females, no difference was found 
in  respect  to  C677T  between  two  groups  (p=0,949). 
Although  the  ratio  differed  markedly  between  two 
groups, the difference did not reach statistical signif-
icance for A1298C (p=0,106), as well (Table 3,4). 
We could not find a difference between the two 
groups when we compare the patient and the control 
groups according to whether they have the risk alleles 
(Table 5).  
 
Table 3. MTHFR C677T Alleles Respect To Sex 
  ADHD  Control  P value 
n  %  n  % 
Male  CC  17  54,8  11  47,8  0,610 
CT and TT  14  45,2  12  52,2 
Female  CC  5  55,6  4  57,1  0,949 
CT and TT  4  44,4  3  42,9 
 
Table 4. MTHFR A1298C Alleles Respect To Sex  
  ADHD  Control  P value 
n  %  n  % 
Male  AA  8  25,8  10  43,5  0,173 
AC and CC  23  74,2  13  56,5 
Female  AA  1  11,1  4  57,1  0,106 
AC and CC  8  88,9  3  42,9 
 
Table 5. The Distribution of Risky and Non-risky Geno-
types 
  ADHD  Control  P value 
n  %  n  % 
Male  Risk genotype  13  24,1  6  11,1  0,228 
Non risk genotype  18  33,3  17  31,5 
Female  Risk genotype  5  31,3  3  18,7  1,000 
Non risk genotype  4  25,0  4  25,0 
Gen-
eral 
Risk genotype  18  25,7  9  12,9  0,202 
Non risk genotype  22  31,4  21  30,0 
risk genotype* : TT/CC, TT/AC, TT/AA, CT/CC, CC/CC, 
CT/AC;  
non risk genotype*: other alleles 
 
Discussion 
MTHFR gene mutations were found related to 
schizophrenia,  depression,  and  bipolar  disorder  in 
studies  searching  relations  between  MTHFR  gene 
mutation and neuropychiatric diseases [13]. Roffman 
et  al  showed  that  MTHFR  C677T  mutation  was  re-
lated to functional deficiency in working memory and 
negative symptoms in schizophrenia [24].  
Folates seem to be of fundamental importance in 
brain  growth,  differentiation,  development,  repair, 
mood, cognition, and ageing [25-28]. These functions 
and their breakdown in folate and vitamin-B12 defi-
ciency are probably primarily mediated through nu-
cleotide  synthesis,  DNA  integrity  and  transcription, 
and  epigenetic  mechanisms,  including  gene  expres-
sion,  relating  to  DNA  methylation  [28].  Neuropsy-
chological  studies  have  found  general  and  specific 
impairments  of  intellectual  function—including  at-
tention,  episodic  and  visuospatial  memory,  and  ab-
stract reasoning—that were attributed to folate defi-
ciency  [25,29].  In  support  of  this,  studies  in  mice 
demonstrated that lesser degrees of gestational folate 
deficiency resulted in a loss of progenitor cells, a net 
reduction  of  cells  in  the  fetal  brain,  reduced  brain 
weight and anxiety-related behaviour in the offspring, 
suggesting a causal effect of prenatal folate status on 
neurodevelopment and behavioural functioning later 
in life [30,31].  Int. J. Med. Sci. 2011, 8 
 
http://www.medsci.org 
527 
As  is  the  norm  for  the  majority  of  psychiatric 
phenotypes,  traditional  aetiological  studies  have  fo-
cused primarily on the interplay between genetic and 
environmental  factors.  Family,  twin,  and  adoption 
studies provide overwhelming evidence for an inher-
ited  contribution  to  the  pathogenesis  of  ADHD  [5]. 
Recent  years  have  seen  considerable  research  effort 
dedicated towards understanding the genetic basis of 
ADHD,  and  replicated  associations  with  polymor-
phisms  in  several  genes  have  been  uncovered  [32]. 
Despite this, we are still a considerable distance from 
fully understanding the inherited causes of ADHD. 
Studies  demonstrating  multifactorial  character-
istics in ADHD etiology necessitate considering this 
point of view in etiological studies assessing this dis-
order. In that situation, different factors contributing 
to current predisposition may precipitate the disease. 
For  example,  in  mothers  carrying  MTHFR  C677T 
homozygote  mutation,  presence  of  folic  acid  defi-
ciency in antenatal period may cause neural crest de-
fects.  Normal  folic  acid  levels  found  in  further  as-
sessments complicates determining this multifactorial 
effect. In our study, normal folic acid levels do not 
imply that the individual’s folic acid levels were in 
normal range during lifetime. Because nutrition and 
mineral demands are supplied from maternal circula-
tion  in  prenatal  period,  the  evaluation  of  maternal 
blood folic acid level is critical. Considering that hu-
man brain develops rapidly in early prenatal period 
and  most  cortical  and  subcortical  structures  are 
formed in 5-25 weeks, evaluation of maternal blood 
folic  acid  level  becomes  more  crucial  [33].  These 
findings  suggest  that  maternal  folic  acid  deficiency 
and fetal or maternal MTHFR mutations (C677T and 
A1298C)  should  be  assessed  together.  Correspond-
ingly, del Rio Garcia et al stated that maternal MTHFR 
polymorphisms  (C677T  and  A1298C)  and  sufficient 
folic acid and B12 vitamin intake in early antenatal 
period is important for the neurobiolological devel-
opment of the infant [34]. This multifactorial interac-
tion  should  be  considered  in  studies  investigating 
gene  mutations  that  contribute  to  intrauterin  envi-
ronmental vulnerability and that are commonly seen 
in  the  general  population.  On  this  point  of  view, 
normal folic acid levels found in the childhood period 
without the assessment of maternal folic acid levels 
do not deny this relation because of the reasons we 
mentioned above. We believe that future studies in-
cluding  large  numbers  of  children  along  with  their 
mother  (particularly  in  the  pregnancy  period)  can 
provide more reliable results. 
Our  study,  which  aimed  to  compare  children 
with and without ADHD according to the presence of 
mutant  allele,  revealed  no  difference  in  respect  to 
MTHFR C677T allele (p=0.678). However, the group 
with ADHD was shown to carry significantly more 
mutant  A1298C  allele  than  the  control  group 
(p=0.033). A previous study by Krull et al [20] has also 
found a relationship between A1298C polymorphism 
and  the  inattentiveness  symptoms  of  ADHD.  It  is 
wellknown that inattentiveness symptoms are prom-
inent in female children with ADHD [35]. In the cur-
rent study, 8 of 9 girls from the ADHD group were 
found  to  have  A1298C  mutation,  but  no  statistical 
difference was found when compared with the con-
trol group (p=0.106). Statistical insignificance despite 
the great difference between percentages may be due 
to the very limited sample size. These findings may 
point to a link between the ADHD and MTHFR gene 
mutations (C677T and A1298C). 
 The most important limitation of this study is its 
small sample size. The literature on the relationship 
between  MTHFR  gene  mutations  (C677T  and 
A1298C)  and  ADHD  is  limited.  Larger  trials  with 
larger patient populations are needed to reach definite 
conclusions whether this mutations is a noteworthy 
risk factor for ADHD. 
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